NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 123 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.33 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,519 | -48.6% | 28,522 | +24.4% | 0.00% | – |
| Q2 2023 | $59,397 | -31.5% | 22,933 | +8.0% | 0.00% | – |
| Q1 2023 | $86,651 | -11.2% | 21,238 | +9.2% | 0.00% | – |
| Q4 2022 | $97,615 | -87.9% | 19,445 | -68.6% | 0.00% | – |
| Q3 2022 | $809,000 | +16.7% | 61,903 | +14.7% | 0.00% | – |
| Q2 2022 | $693,000 | -17.7% | 53,980 | -2.3% | 0.00% | – |
| Q1 2022 | $842,000 | -8.5% | 55,238 | +6.4% | 0.00% | – |
| Q4 2021 | $920,000 | -11.0% | 51,925 | +5.5% | 0.00% | – |
| Q3 2021 | $1,034,000 | +249.3% | 49,195 | +228.2% | 0.00% | – |
| Q2 2021 | $296,000 | -70.7% | 14,991 | -56.9% | 0.00% | – |
| Q1 2021 | $1,011,000 | -56.8% | 34,766 | -55.0% | 0.00% | -100.0% |
| Q4 2020 | $2,338,000 | +234.0% | 77,178 | +75.3% | 0.00% | – |
| Q3 2020 | $700,000 | -6.3% | 44,017 | +16.3% | 0.00% | – |
| Q2 2020 | $747,000 | – | 37,832 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |